Original Publication Date: 18 March, 2014
Publication / Source: International Journal of Hematologic Oncology
Authors: Maurizio Musso, Ferdinando Porretto, Renato Scalone, Alessandra Crescimanno, Vita Polizzi & Vincenza Bonanno
Autologous stem cell transplantation (ASCT), in chemosensitive relapsed patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL), is associated with superior event-free survival (EFS) compared with salvage chemotherapy alone. BEAM is one of the most commonly used regimens in both HL and NHL because of its acceptable toxicity and high effectiveness. The nonrelapsed mortality (NRM) ranges from 7 to 10% in historical studies. More recent investigations have demonstrated a lower NRM, probably due to various factors such as the use of peripheral blood precursor cells and better support therapy.